Whitehawk Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs

Whitehawk Therapeutics

12/03/2026 12:10

Overview

U.S. oncology therapeutics firm's Q4 net loss widened, missing analyst expectations

Product sales revenue fell to zero in Q4 as focus shifted to ADC clinical programs

Outlook

Company expects to submit IND for HWK-206 in mid-2026 and start Phase 1 in Q3 2026

Initial results from HWK-007 and HWK-016 Phase 1 trials expected in 1H 2027

Company anticipates cash balance will fund operations into 2028

Result Drivers

PIPELINE ADVANCEMENT - Co attributed increased operating expenses and focus in Q4 to advancing Phase 1 ADC trials (HWK-007, HWK-016) and IND-enabling work for HWK-206

RESEARCH AND DEVELOPMENT SPENDING - Higher research and development costs drove up Q4 operating expenses

Company press release: ID:nPn940rjWa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
Miss
-$23.25 mln
-$19.36 mln (4 Analysts)
Q4 Operating Expenses
$24.89 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $6.00, about 49.6% above its March 11 closing price of $4.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)